LearnGlossaryMarketStocksSuperinvestorsSign in

XNCR

Xencor, Inc.

Healthcare · $1.8B market cap

Verdict

We can't put a fair value on XNCR right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

3 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth28.2% a year✓
Equity per share growth8.6% a year✗
Sales growth17.5% a year✓
Free cash flow growth23.4% a year✓
Return on invested capital-18.7%✗

Follow XNCR

Track it on your watchlist and see the full analysis. Free.

Create a free account

About Xencor, Inc.

Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works